Recent developments include a 2026 asthma maintenance indication for a triple-combination inhaler and a selected COPD indication for a targeted biologic. The April 2026 Breztri label and May 2025 Nucala label are useful examples. They do not create a single newest or best treatment for everyone with asthma or COPD.
When a headline catches your attention, identify the condition, age group and treatment role before comparing names. The same brand can appear in more than one disease pathway without making the prescriptions interchangeable.
A shared brand still needs the correct indication
The Breztri prescribing information revised April 2026 identifies budesonide, glycopyrrolate and formoterol fumarate. It lists maintenance treatment of COPD in adults and maintenance treatment of asthma in adults and children aged 12 and older. It is not indicated for relief of acute bronchospasm.
That is a dated label description, not advice to replace an inhaler or use an existing COPD product as your asthma prescription. Ask the clinician and pharmacist which exact prescribed product and instructions apply. This page gives no strength comparison or conversion.
UK guidance recommends explaining each inhaler’s contents and checking use. More ingredients do not remove the need for that teaching. Ask what the proposed change is meant to improve and how it fits the rest of the plan.
A targeted option has population limits
The Nucala label’s COPD indication concerns add-on maintenance treatment for adults with inadequately controlled disease and an eosinophilic phenotype. Its severe-asthma indication is separate. Neither should be shortened to a recommendation for everyone with the disease.
Another selected asthma development is Exdensur’s December 2025 severe eosinophilic asthma maintenance indication for patients aged 12 and older. Maintenance roles must remain distinct from attack treatment.
Safety remains part of the decision. The Nucala label includes hypersensitivity warnings and cautions against abruptly discontinuing corticosteroids when treatment begins. Ask what assessment supports the proposed option, what continues and how risks will be addressed. Novelty is not a substitute for suitability.
Review the unmet need, not just the newest medicine
Assessment of poor asthma control includes technique, treatment use, other conditions and exposures. A new-drug conversation should not skip those possibilities. Describe the problem the change is supposed to solve rather than requesting a product because it appears in a news story.
Rehabilitation can add assessed activity and education. The ATS adult guideline supports rehabilitation for stable COPD and after COPD hospitalization. Care may therefore need a service, teaching or access support as well as a medicine discussion.
These are selected dated US developments, checked against primary documents, not an exhaustive list of every 2026 approval or the latest full label for every product. Ask for current local prescribing information and an individual decision before making any change.
Sources and scope
The FDA documents support their stated roles and dates. UK guidance and ATS recommendations have separate purposes and populations. Not yet medically reviewed.
Related posts:
What Are Biologics, And How Can They Help With Severe Asthma?
How Do You Tell What Stage Of COPD You Are In?
What Is The Life Expectancy Of A Person With COPD?
What Are The Best Practices For COPD Management?
How Does Nutrition Affect COPD, And Are There Dietary Recommendations For Managing It?
How Can Pulmonary Rehabilitation Benefit Someone With COPD?